Aktienanalyse zu QuidelOrtho Corp (QDEL)QDELQuidelOrtho Corp

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Optix and others. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

QuidelOrtho Corp (QDEL) appears to be a good buy right now due to its recent stock surge of 35% following news of a potential sale of its testing business for approximately $1.5 billion, which could significantly alleviate its $3.8 billion debt burden. The current price of $13.73 is below the average analyst price target of $18.63, indicating a potential upside of about 35%. Additionally, the RSI is at 57.32, suggesting that the stock is neither overbought nor oversold, providing a favorable entry point for long-term investors. However, the company has faced significant losses, with a net income of -$733 million in Q3 2025, which remains a risk factor to consider.

7 analysts cover QDEL: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 35.00.